Pfizer's Obesity Gambit: Why Monthly Dosing Is a Narrow Edge

THE WEIGHT-LOSS drug market is now a three-cornered fight. Eli Lilly and Novo Nordisk have spent the past four years duelling for the title of world's biggest drugmaker. Pfizer, having failed to develop a GLP-1 therapy of its own, has tried to buy its way into the ring. The question is whether its main candidate, berobenatide, has enough of an edge to justify the price of entry.

Pfizer acquired Metsera... in November 2025 for roughly $7bn, with potential milestone payments taking the total to over $10bn. Berobenatide (PF-08653944), an ultra-long-acting GLP-1 receptor agonist (the class of hormone-mimicking drugs behind Novo's Wegovy and Lilly's Mounjaro), is the most advanced asset in that portfolio. Pfizer plans to advance 10 Phase 3 studies in 2026. The company is also pruning redundant obesity assets, as it did in August when it dropped two clinical programmes, including an overlapping GLP-1 acquired in the same deal. The signal is deliberate: berobenatide is the bet.

Its proposed advantage is monthly maintenance dosing. After 12 weeks of weekly injections, patients would switch to a single monthly shot. The idea is simple. Obesity is a lifelong condition. Patients who lose weight on weekly injections often stop taking them because the regimen is inconvenient. A monthly drug should lose fewer patients along the way, and adherence is the industry's silent profit driver.

The Phase 2b data, presented at the American Diabetes Association meeting in June, offer support without delivering a knockout. In a trial of adults with obesity but no diabetes, the highest tested monthly dose achieved a 12.3% placebo-adjusted weight loss at 28 weeks. In a separate weekly-dosing study, 15.9% absolute weight loss was observed at 32 weeks. Patients with type 2 diabetes saw up to 10.2% weight reduction and a 2.2 percentage-point drop in HbA1c. Gastrointestinal side effects, the class's signature burden, were mostly mild or moderate; 83-88% of treated patients reported little or only mild discomfort.

Those numbers look respectable. The trouble is that respectability is not a differentiator in a market where the benchmarks are set by drugs that produce larger results. Zepbound, Lilly's dual GIP/GLP-1 agonist tirzepatide, routinely delivers 15-20% weight loss over a year in late-stage trials. Lilly's next-generation triple agonist retatrutide, now in Phase 3, achieved 28.3% weight loss at 80 weeks in one study. Berobenatide is a single GLP-1 receptor agonist. It has no structural path to surpass a dual or triple agonist on pure potency.

To be sure, cross-trial comparisons are imperfect. Pfizer's Phase 3 programme will test doses up to 9.6mg monthly, double the highest amount used in Phase 2. The company says it sees no plateau in the weight-loss trajectory, suggesting higher doses could push results further. And adherence matters: a drug taken once a month, even if marginally less potent, may produce better real-world outcomes than a weekly drug that patients abandon.

Yet the tolerability data raise a question. In the Phase 2b monthly-dosing study, 10% of participants on the planned late-stage regimen discontinued due to adverse events. That is nearly double the roughly 6% discontinuation rate Lilly observed for Zepbound's highest dose in Phase 3. The switch from weekly to monthly dosing also produced a mild, transient spike in nausea and vomiting. Pfizer's executives have pointed out that no sudden jump in side effects occurred at the transition. True enough. But a 10% dropout rate is a signal, not a rounding error.

The commercial landscape makes the clinical gap harder to bridge. Lilly is not standing still. Tirzepatide's two branded forms — Mounjaro for diabetes, Zepbound for obesity — were the world's best-selling drugs in 2025, with combined sales of $36.5bn. Lilly projects 2026 revenue of $85-87bn, up from earlier guidance, driven by volume growth that is outpacing a 13% decline in realised prices. About 75% of new GLP-1 patient starts are already on injectables, and roughly 80% of patients in the new Medicare obesity pilot chose injections over oral options. Meanwhile retatrutide, with its superior efficacy profile, is expected to file for FDA approval this year.

Novo Nordisk is under pressure but not defeated. The company forecasts a 5-13% decline in profit and sales in 2026, citing pricing headwinds, competition and the expiry of semaglutide patents outside the United States. Its oral Wegovy pill has sold three million prescriptions since a January launch, a respectable showing. But Novo is the weaker of two incumbents, and Pfizer would need to leapfrog both to win.

Pricing dynamics add another layer. The White House has negotiated a $245 net price per month for GLP-1 medications sold through a new Medicare programme that began in July. Under the arrangement, beneficiaries pay a $50 co-payment while manufacturers cover the difference between wholesale acquisition cost and the negotiated price. The policy was designed to expand access while controlling costs. For new entrants, it has the unintended effect of compressing the pricing premium that a differentiated product might command. A monthly drug cannot easily charge more if the system is moving towards a uniform price floor.

This is where the structural picture sharpens. Pfizer is betting that convenience alone can compensate for inferior efficacy in a market where efficacy is the dominant competitive variable. The incentive logic is clear. Pfizer cannot out-innovate Lilly on mechanism, having failed in-house with its own oral GLP-1, danuglipron, which was scrapped in April 2025 after a liver injury signal. It cannot match Novo's first-mover brand advantage. Monthly dosing is the only structural lever left.

Whether that is enough depends on three questions. First, will higher Phase 3 doses close the efficacy gap to within an acceptable margin? Second, will adherence gains from monthly dosing be large enough to offset the tolerability concern, or will the 10% dropout rate hold? Third, will the pricing environment of 2028-29, when berobenatide might launch, still allow a newcomer to capture share from two entrenched incumbents?

The first two questions will be answered by trial data. The third is a matter of arithmetic. If the GLP-1 market is indeed moving towards $245 net prices, then the winner will be the drug that keeps patients on therapy for the longest time at the lowest cost per injection. Monthly dosing helps on frequency but not on side effects, and side effects drive discontinuation.

For investors, the risk is not that berobenatide will fail in the clinical sense. The risk is that it will succeed modestly, earn a slice of the market, and prove that the $10bn price tag was fair. The larger danger is that it arrives after retatrutide has already set a new efficacy standard, leaving Pfizer's monthly GLP-1 looking like a good-enough product in a market that rewards the best. That would not be a disaster. It would be an expensive tie.

Pfizer's wider thesis — that obesity and oncology will replace the covid-era revenue spike — still holds. But in the obesity space, the company is buying a seat at the table rather than a path to the head of it. Better to start late than not at all. But the maths must work.